Impact BioMedical Inc IBO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
-
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
-
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
-
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
Trading Information
- Previous Close Price
- $3.40
- Day Range
- $2.62–4.08
- 52-Week Range
- $2.62–10.47
- Bid/Ask
- $2.98 / $3.30
- Shares Outstanding
- 8.54M
- Market Cap
- $26.98M
- Volume/Avg
- 29,041 / 11,856
Key Statistics
- Price/Earnings (Normalized)
- 93.01
- Price/Sales
- 715.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.impactbiomedinc.com
Valuation
|
Metric
|
IBO
|
|---|---|
Price/Earnings (Normalized) | 93.01 |
Price/Book Value | 3.16 |
Price/Sales | 715.31 |
Price/Cash Flow | — |
Price/Earnings
IBO
Financial Strength
|
Metric
|
IBO
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.16 |
Interest Coverage | −5.93 |
Quick Ratio
IBO
Profitability
|
Metric
|
IBO
|
|---|---|
Return on Assets (Normalized) | 10.91% |
Return on Equity (Normalized) | 76.82% |
Return on Invested Capital (Normalized) | 14.52% |
Return on Assets
IBO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x^?!@pk | LOCK|^q^& | $129B | |||
| Moderna Inc
MRNA
| LOCK|B!@zMd | LOCK|$P | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|P^$P>$x | LOCK|Qc^S | $82B | |||
| argenx SE ADR
ARGX
| LOCK|r<s$@Yc | LOCK|hk | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r<%?Mx | LOCK|Lk | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?h#bBKr | LOCK|gm^Mg | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|DQ%%tL#R | LOCK|f$j< | $27B | |||
| Incyte Corp
INCY
| LOCK|!#RW<^Q | LOCK|&y! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|c?$P^kl | LOCK|fm | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&###R^ | LOCK|>@ | $14B |
United States